human bfgf elisa kit  (Boster Bio)

Journal: Journal of Bone Oncology

Article Title: Doxorubicin enhances adipogenesis in an FGF2-dependent manner and induces a tumour-promoting secretory phenotype

doi: 10.1016/j.jbo.2026.100754

Figure Lengend Snippet: Doxorubicin increases both intracellular and secreted protein levels of FGF2, and depletion of FGF2 impedes doxorubicin-enhanced adipogenesis. A) Protein expression of FGF2 at day 10 following treatment with vehicle control or 25 nM doxorubicin at day 9. Densitometry of FGF2 bands normalized to GAPDH as an endogenous loading control is shown for the high molecular weight (HMW) and low molecular weight (LMW) isoforms from 3 independent biological replicate blots. B) Secreted FGF2 (pg/mL) as detected by ELISA in conditioned supernatant at day 10 following vehicle control or 25 nM doxorubicin treatment at day 9 of adipogenic differentiation. C) Schematic for adipogenic differentiation of human MSC treated on day 9 of differentiation with vehicle control or 25 nM doxorubicin and subsequently transfected with 100 nM non-targeting siRNA or siRNA targeting FGF2 and assessed at day 12 by RT-qPCR and BODIPY staining. D) RNA isolated as per (C), was used to confirm siRNA-mediated depletion of FGF2 gene expression by RT-qPCR. E) Representative images of BODIPY stained cells treated as per (C) (left), with fold change in the percentage of BODIPY+ cells with doxorubicin treatment as compared to the vehicle control treatment for each siRNA condition enumerated and graphically represented (right). F) Gene expression of PPARG was measured using RT-qPCR at day 12 following treatment as in (C). Graphs show the mean ± SEM. Statistical tests are unpaired t -test in Fig A) and B) and one-way ANOVA in Fig D), E) and F) (*p < 0.05; **p < 0.01; ***p < 0.001), n = 3 biological replicates each with 3 technical replicates.

Article Snippet: ELISA to measure protein concentration of FGF2 in conditioned supernatants was performed using the Quantikine ELISA kit (cat #DFB50, R&D Systems, Minneapolis, MN), according to manufacturer’s instructions.

Techniques: Expressing, Control, High Molecular Weight, Molecular Weight, Enzyme-linked Immunosorbent Assay, Transfection, Quantitative RT-PCR, Staining, Isolation, Gene Expression

Journal: Frontiers in Physiology

Article Title: Uncovering the mechanism of arecoline’s effect on oral submucous fibrosis: integrating transcriptomics and in vitro and in vivo experiments

doi: 10.3389/fphys.2026.1768602

Figure Lengend Snippet: Arecoline-induced fibrosis in hOMF cells. (A) Experimental design flowchart; (B) Effects of different doses of arecoline on hOMF cell viability at 24h ( x ¯ ±s, n = 3); (C) Effects of different doses of arecoline on hOMF cell viability at 48h ( x ¯ ±s, n = 3); (D) Effects of different doses of arecoline on hOMF cell viability at 72h ( x ¯ ±s, n = 3); (E) Immunofluorescence staining of α-SMA expression in hOMF cells treated with arecoline (n = 3); (200x); (F) Immunofluorescence staining of Col1a1 expression in hOMF cells treated with arecoline (n = 3); (200x); (G) Quantitative analysis of α-SMA fluorescence intensity ( x ¯ ± s , n = 3); (H) Quantitative analysis of Col1a1 fluorescence intensity ( x ¯ ±s, n = 3). (I) Protein expression levels of bFGF ( x ¯ ±s, n = 3); (J) Protein expression levels of TGF-β1 ( x ¯ ±s, n = 3); (K) Relative mRNA expression levels of YAP ( x ¯ ±s, n = 3); (L) Relative mRNA expression levels of TAZ ( x ¯ ±s, n = 3). Compared with the Control group, * P < 0.05, ** P < 0.01.

Article Snippet: Primers were designed by Wuhan Kingwell Biotechnology Co., Ltd. TGF-β (E-EL-0162) and bFGF (E-EL-H6042) ELISA kits, as well as the Enhanced Cell Counting Kit 8 (WST-8/CCK8) (E-CK-A362), were purchased from Elabscience Biotechnology (Wuhan, China).

Techniques: Immunofluorescence, Staining, Expressing, Fluorescence, Control

Journal: Regenerative Biomaterials

Article Title: AI-guided design and optimization of a novel KIM-1-targeted peptide for bFGF delivery in acute kidney injury repair

doi: 10.1093/rb/rbag050

Figure Lengend Snippet: Construction and bioactivity evaluation of WEV-bFGF. ( A ) Spatial structure prediction of WEV-bFGF recombinant protein and natural bFGF; ( B ) SDS-PAGE of bFGF, KIT-bFGF and WEV-bFGF; ( C ) Western blot of native bFGF, KIT-bFGF and WEV-bFGF; ( D ) The biological activities of native bFGF, KIT-bFGF and WEV-bFGF by CCK-8 assay; ( E ) The fluorescence distribution of Delight 800 labeled recombinant proteins in hypoxic HK-2 cells; ( F ) Statistical analysis of fluorescence intensity of Dylight 800 in hypoxic HK-2 cells; Scale bar = 25 μm; ( G ) The protective effects of recombinant proteins on HK-2 cells after hypoxic injury by the CCK8 assay. All quantitative data are presented as mean ± SD, * P < 0.05, ** P < 0.01.

Article Snippet: Subsequently, in accordance with the instructions of the Human bFGF ELISA Kit (EK0441, Boster, China), the protein extracted from kidney tissue and the content of bFGF in serum were determined.

Techniques: Recombinant, SDS Page, Western Blot, CCK-8 Assay, Fluorescence, Labeling

Journal: Regenerative Biomaterials

Article Title: AI-guided design and optimization of a novel KIM-1-targeted peptide for bFGF delivery in acute kidney injury repair

doi: 10.1093/rb/rbag050

Figure Lengend Snippet: The evaluation of targeting capacity of WEV-bFGF in ischemic kidney in vivo . ( A ) At 6 h after administration, the in vivo fluorescence distribution of Dylight800-labeled recombinant proteins in major organs of AKI-injured rats by the small animal imaging system; ( B ) Western blot showing bFGF protein expression in ischemic renal tissue 6 h after administration; ( C ) Quantitative analysis of relative bFGF protein expression at 6 h; ( D ) The content of bFGF in ischemic kidneys by ELISA assay at 6 h after administration; ( E ) The content of bFGF in serum at 6 h after administration; ( F ) Immunofluorescence colocalization of bFGF and KIM-1 in the frozen sections at 6 h after administration, Scale bar = 50 μm; ( G ) Colocalization analysis of PBS, bFGF, KIT-bFGF and WEV-bFGF groups at 6 h after administration; ( H ) At 24 h after administration, the in vivo fluorescence distribution of Dylight800-labeled recombinant proteins in major organs of AKI-injured rats by the small animal imaging system; ( I ) Western blot showing bFGF protein expression in ischemic renal tissue 24 h after administration; ( J ) Quantitative analysis of relative bFGF protein expression at 24 h; ( K ) The content of bFGF in ischemic kidneys by ELISA assay at 24 h after administration; ( L ) The content of bFGF in serum at 24 h after administration; ( M ) Immunofluorescence staining showing colocalization of bFGF and KIM-1 at 24 h after administration, scale bar = 50 μm; ( N ) Colocalization analysis of PBS, bFGF, KIT-bFGF and WEV-bFGF groups at 24 h after administration. All quantitative data are presented as mean ± SD, * P < 0.05, ** P < 0.01, N = 8.

Article Snippet: Subsequently, in accordance with the instructions of the Human bFGF ELISA Kit (EK0441, Boster, China), the protein extracted from kidney tissue and the content of bFGF in serum were determined.

Techniques: In Vivo, Fluorescence, Labeling, Recombinant, Imaging, Western Blot, Expressing, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining

Journal: Regenerative Biomaterials

Article Title: AI-guided design and optimization of a novel KIM-1-targeted peptide for bFGF delivery in acute kidney injury repair

doi: 10.1093/rb/rbag050

Figure Lengend Snippet: Functional tests and morphological analysis of the kidneys. ( A ) Experimental design of WEV-bFGF for the treatment of I/R; ( B ) Statistical analysis of serum Scr content for renal function evaluation at 24 h after renal I/R injury in rats; ( C ) Statistical analysis of serum Scr content for renal function evaluation at 24 h after renal I/R injury in rats; ( D ) H&E staining for kidney histopathological evaluation after I/R injury. Arrows indicated the sites of renal tubular injury. Scale bar = 20 μm; ( E ) Statistical analysis of renal tubular injury score; ( F ) MASSON staining for renal tissue fibrosis evaluation after I/R injury. Scale bar = 50 μm; ( G ) Statistical analysis of renal tissue fibrosis. All quantitative data are presented as mean ± SD, * P < 0.05, ** P < 0.01, N = 8.

Article Snippet: Subsequently, in accordance with the instructions of the Human bFGF ELISA Kit (EK0441, Boster, China), the protein extracted from kidney tissue and the content of bFGF in serum were determined.

Techniques: Functional Assay, Staining

Journal: Regenerative Biomaterials

Article Title: AI-guided design and optimization of a novel KIM-1-targeted peptide for bFGF delivery in acute kidney injury repair

doi: 10.1093/rb/rbag050

Figure Lengend Snippet: Transcriptome analysis of potential mechanism in WEV-bFGF mediating ischemic renal repair. ( A ) Volcano plots of gene differences between the WEV group and the PBS group; ( B ) KEGG analysis between the WEV group and the PBS group; ( C ) Volcano plots of gene differences between the WEV-BFGF group and the bFGF group; ( D ) KEGG analysis between the WEV-bFGF group and the bFGF group; ( E ) Heat map of differentially expressed genes related to repair and regeneration of AKI; ( F ) Quantitative PCR validation of key gene expression. All quantitative data are presented as mean ± SD, * P < 0.05, ** P < 0.01, N = 6.

Article Snippet: Subsequently, in accordance with the instructions of the Human bFGF ELISA Kit (EK0441, Boster, China), the protein extracted from kidney tissue and the content of bFGF in serum were determined.

Techniques: Real-time Polymerase Chain Reaction, Biomarker Discovery, Gene Expression